Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | AHR | P35869 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14375274 | 0.82 | AHR (0.42) | CYP2A6CYP1A2AHRMEN1KMT2A | |
| SCHEMBL7832295 | 0.78 | CYP1A2 (0.42) | CYP2A6CYP1A2AHRMEN1KMT2A | |
| SCHEMBL8723829 | 0.75 | CYP2A6 (0.37) | CYP2A6CYP1A2AHRMEN1KMT2A | |
| SCHEMBL7298577 | 0.75 | MEN1 (0.37) | CYP2A6CYP1A2AHRMEN1KMT2A | |
| SCHEMBL29344202 | 0.75 | CYP2A6 (0.37) | CYP2A6CYP1A2AHRMEN1KMT2A | |
| SCHEMBL5255668 | 0.75 | AHR (0.37) | CYP2A6CYP1A2AHRMEN1KMT2A | |
| SCHEMBL8723827 | 0.75 | CYP2A6 (0.37) | CYP2A6CYP1A2AHRMEN1KMT2A | |
| SCHEMBL2362910 | 0.72 | ALDH1A1 (0.61) | CYP2A6CYP1A2AHRMEN1KMT2A | |
| SCHEMBL4767088 | 0.70 | CYP2A6 (0.44) | CYP2A6CYP1A2MEN1KMT2ATSHR | |
| SCHEMBL29620230 | 0.69 | TSHR (0.53) | CYP2A6CYP1A2AHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1361225-B1 | COMPOUNDS SUBSTITUTED WITH BICYCLIC AMINO GROUPS | SANKYO CO (JP) | 2007-11-07 | — | — | EP | disclosed |
| US-7122666-B2 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-10-17 | — | — | US | disclosed |
| US-7091352-B2 | Compounds substituted with bicyclic amino groups | SANKYO COMPANY, LIMITED (JP) | 2006-08-15 | — | — | US | disclosed |
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1377577-B1 | PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES | SANKYO CO (JP) | 2006-06-14 | — | — | EP | disclosed |
| US-20050283006-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2005-12-22 | — | — | US | disclosed |
| CN-1525968-A | composition for preventing or treating liver disease | 三共株式会社 | 2004-09-01 | — | — | CN | disclosed |
| US-20040147525-A1 | Compounds substituted with bicyclic amino groups | SANKYO COMPANY, LIMITED (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1070711-B1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO CO (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-0299974-B1 | ANTHELMINTIC ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS | THE UPJOHN COMPANY (US) | 1992-01-22 | — | — | EP | disclosed |
| US-5049561-A | Anthelmintic acylhydrazones, method of use and compositions | THE UPJOHN COMPANY (US) | 1991-09-17 | — | — | US | disclosed |
| US-5023334-A | Anthelmintic pyridinyl acylhydrazones | THE UPJOHN COMPANY (US) | 1991-06-11 | — | — | US | disclosed |
| US-5011932-A | Anthelmintic pyridinyl acylhydrazones derivatives | UPJOHN COMPANY (US) | 1991-04-30 | — | — | US | disclosed |
| EP-0370065-A1 | ANTHELMINTIC ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS | THE UPJOHN COMPANY (US) | 1990-05-30 | — | — | EP | disclosed |
| WO-1989000992-A1 | ANTHELMINTIC ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS | THE UPJOHN COMPANY (US) | 1989-02-09 | — | — | WO | disclosed |
| EP-0299973-A1 | ANTHELMINTIC ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS. | UPJOHN CO (US) | 1989-01-25 | — | — | EP | disclosed |
| EP-0299974-A1 | ANTHELMINTIC ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS. | UPJOHN CO (US) | 1989-01-25 | — | — | EP | disclosed |
| WO-1987006133-A1 | ANTHELMINTIC ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS | THE UPJOHN COMPANY (US) | 1987-10-22 | — | — | WO | disclosed |
| WO-1987006127-A1 | ANTHELMINTIC ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS | THE UPJOHN COMPANY (US) | 1987-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1A, IL1B | CYP2A6 978/4885CYP1A2 665/4885AHR 186/4885 |
| US-20050283006-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, CNKSR1, IL1A | CYP2A6 855/4885CYP1A2 558/4885AHR 180/4885 |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1B, IL1A | CYP2A6 997/4885CYP1A2 397/4885AHR 67/4885 |
| US-20040147525-A1 | Compounds substituted with bicyclic amino groups | IL2, IL1B, IL4I1 | CYP2A6 819/4885CYP1A2 174/4885AHR 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.